• Download mobile app
16 Jan 2021, Edition - 2013, Saturday

Trending Now

  • #COVID19 Covishield dispatch for vaccine drive a historic moment: Serum Institute of India
  • Dynastic politics burdens country with incompetence: PM Modi
  • Will take decision on resumption of physical court hearing after consulting medical experts: SC

Businesswire

Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress

by businesswireindia.com

Share
Business Wire India
  • Data from key trials will aid in increasing scientific understanding of ESUS and CVT
  • RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa® vs ASA

Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®).

 

The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexilate with acetylsalicylic acid (ASA) in any indication, will add further insight into the prevention of secondary stroke in patients with an embolic stroke of undetermined source (ESUS).1 As the first comparison to ASA, this trial will also offer further important insights into the clinical profile of dabigatran etexilate.

 

RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It is the first exploratory, prospective, randomised controlled study of any non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinuses of the brain.

 

Both trials are part of Boehringer Ingelheim’s ongoing commitment to expanding scientific knowledge of stroke prevention and form part of the extensive RE-VOLUTION® clinical trial programme for dabigatran etexilate, which upon completion will have enrolled more than 60,000 patients worldwide.1-14

 

The results from these two trials will be presented in the following sessions:

 
Abstract title   Presentation details  
RE-SPECT ESUS: Dabigatran versus acetylsalicylic acid for stroke prevention in patients with embolic stroke of undetermined source   Wednesday 17 October, 19:10 – 19:30, HALL A

Session code: AWA01

 

Session title: Opening: late-breaking trials

 

Presentation number: 100

 
RE-SPECT CVT: Randomized controlled trial of the safety and efficacy of dabigatran etexilate vs. dose-adjusted warfarin in patients with cerebral venous thrombosis   Saturday 20 October, 11:30 – 11:50, HALL B

Session code: AWA03

 

Session title: Award lectures & late breaking trials

 

Presentation number: 101

 

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/Results-from-two-Pradaxa-trials-to-be-presented-at-WSC

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

 

 

 

 
Source: Businesswire
COIMBATORE WEATHER